CliffBio
small molecule

SYMJEPI

EPINEPHRINE

Loss of exclusivityOctober 2036latest FDA-listed patent expiry
CompanyAdamis Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameSYMJEPI
Active ingredientEPINEPHRINE
Strength0.15MG/0.3ML (0.15MG/0.3ML)
Dosage formSOLUTION
RouteINTRAMUSCULAR, SUBCUTANEOUS
ModalitySmall molecule
FDA approvalSeptember 2018
Marketing statusDISCN

Listed patents

PatentExpiresType
11141540October 2036product

More from Adamis Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SYMJEPI patent cliff — loss of exclusivity October 2036 | CliffBio